|By PR Newswire||
|February 10, 2014 06:01 PM EST||
DUBLIN, February 10, 2014 /PRNewswire/ --
Dublin - Research and Markets (http://www.researchandmarkets.com/research/3q7md6/immunoassay) has announced the addition of the "Immunoassay Market by Technology, Analyzers & Reagents, Applications & End Users - Global Forecast to 2018" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
The global market is segmented on the basis of technology, application, product (analyzers and reagents), and end user. The global market, by technology, is further segmented into enzyme, fluorescent, chemiluminescence immunoassay, radioimmunoassay, and others. Enzyme and chemiluminescence immunoassay are two of the largest segments, accounting for a total of -65% of the market share globally in 2012.
By application, this market has segments like oncology, infectious diseases, cardiology, bone and mineral, endocrinology, autoimmunity, toxicology, hematology, neonatal screening, and others. Infectious disease is the largest segment with more than one-third share of the total market. This is attributed to the increasing prevalence of infectious diseases along with continuous product innovations and launches.
The global market is valued around $13.0 billion in 2013 and is expected to grow at a healthy CAGR of 8.1% to reach $19.1 billion by 2018. Expanding use of immunoassay, increasing demand for high-quality healthcare services, and rapidly increasing geriatric population are the major factors driving the global market. New and innovative product launches by the key industry players also boost the market. However, the rising commoditization of certain immunoassay, uncertain regulatory environment, and reduction in the healthcare budget are critical restraints for the growth of the market.
The key market vendors in this arena are Abbott Laboratories (U.S.), Alere, Inc. (U.S.), Danaher Corporation (U.S.), DiaSorin S.P.A. (Italy), Ortho Clinical Diagnostics (U.S.), Roche Diagnostics (Switzerland), Siemens Healthcare (Germany), and Sysmex Corporation (Japan).
Key Topics Covered:
2 Executive Summary
3 Premium Insights
4 Industry Analysis & Market Overview
5 Immunoassay Market, By Technology
6 Immunoassay Market, By Products (Analyzers & Reagents)
7 Immunoassay Market, By Application
8 Global Immunoassay Market, By End-Users
9 Geographic Analysis
10 Competitive Landscape
11 Company Profiles
- Abbott Laboratories, Inc
- Alere, Inc
- Becton, Dickinson And Company
- DRG International, Inc
- Danaher Corporation (Beckman Coulter)
- Diasorin SPA
- Diasource Immunoassays SA
- Hologic (Gen-Probe )
- IBL International GMBH
- IDS Plc
- Meridian Life Science, Inc
- Ortho Clinical Diagnostics (A J&J Company)
- Qiagen NV
- Roche Diagnostics Limited
- Siemens Healthcare
- Sysmex Corporation
- Thermo Fisher Scientific, Inc (Brahms)
For more information visit http://www.researchandmarkets.com/research/3q7md6/immunoassay
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
Aug. 28, 2015 02:00 PM EDT
Aug. 28, 2015 12:45 PM EDT Reads: 436
Aug. 28, 2015 12:30 PM EDT
Aug. 28, 2015 12:30 PM EDT Reads: 137
Aug. 28, 2015 12:30 PM EDT
Aug. 28, 2015 12:07 PM EDT
Aug. 28, 2015 12:00 PM EDT Reads: 177
Aug. 28, 2015 12:00 PM EDT Reads: 440
Aug. 28, 2015 11:30 AM EDT
Aug. 28, 2015 11:15 AM EDT Reads: 799
Aug. 28, 2015 11:00 AM EDT
Aug. 28, 2015 10:00 AM EDT Reads: 257
Aug. 28, 2015 10:00 AM EDT
IBM’s Blue Box Cloud, powered by OpenStack, is now available in any of IBM’s globally integrated cloud data centers running SoftLayer infrastructure. Less than 90 days after its acquisition of Blue Box, IBM has integrated its Blue Box Cloud Dedicated private-cloud-as-a-service into its broader portfolio of OpenStack® based solutions. The announcement, made today at the OpenStack Silicon Valley event, further highlights IBM’s continued support to deliver OpenStack solutions across all cloud depl...
Aug. 28, 2015 09:45 AM EDT Reads: 142
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, will discuss how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a prac...
Aug. 28, 2015 09:45 AM EDT Reads: 172